Biomedical subjects

John F Chapman

Publications and source records attributed to John F Chapman.

6 recordsLinked to original sources

PubMed2006

Mental health service provision in juvenile justice facilities: pre- and postrelease psychiatric care.

High prevalence rates of mental illness among adolescents in juvenile justice facilities require multifaceted interventions. Children entering justice systems are frequently underserved and having their first contact with psychiatric services. Programming must be multidisciplinary and multifaceted, combining treatment within the facility with postrelease planning. It examines the role of the psychiatrist and the structure of mental health services within juvenile justice facilities.

Adolescent↗

PubMed2006

Mental health care in juvenile detention facilities: a review.

Juvenile detention facilities have come under increasing legal pressure to provide mental health services to detainees, and mental health clinicians may be asked to design and implement programs in detention facilities. However, there is little consensus on what types of services should be provided, and virtually no data on the effectiveness of such services in a detention setting. The objective of this article is to provide an overview of the existing literature on mental health services in juvenile detention and to make suggestions about future research needs. Specifically, it highlights the tension surrounding the provision of mental health care in juvenile detention, presents data on the prevalence of psychiatric problems in detention settings and what types of services are currently provided, and draws on the larger child and adolescent mental health literature to suggest what types of services might be most appropriate for juvenile detention settings. We conclude that, although there are some suggestions of promising interventions that may be appropriate, much more research, specifically in detention settings, is needed to determine their effectiveness.

Adolescent↗

PubMed2005

Predicting respiratory distress syndrome using gestational age and fetal lung maturity by fluorescent polarization.

OBJECTIVE: This study was undertaken to design a predictive model for assessing the risk of developing respiratory distress syndrome (RDS) by using gestational age (GA) and results from a quantitative fluorescence polarization-based fetal lung maturity assay (TDx FLM II). STUDY DESIGN: The study populations from the 3 largest published studies analyzing the association between TDx-FLM II and the development of RDS were combined for this analysis. A total of 509 patients were included in this study; 57 gave birth to infants who had RDS develop, and 452 gave birth to infants who were unaffected. Logistic regression analysis was used to model the odds of RDS as a function of GA, TDx FLM II ratio, and study site. RESULTS: The absolute and relative risks of an infant having RDS develop as a function of GA and TDx FLM II were calculated. The odds of RDS decrease 31% for each increasing week of GA and decrease 67% for each 10 mg/g increase in the TDx FLM II ratio. GA-specific TDx FLM II cutoffs are provided for sensitivities between 84% and 100%. The bias-adjusted area under the receiver-operating characteristic curve for the classification of RDS, based on GA and TDx FLM II ratio, was 0.957 with the use of the logistic model. CONCLUSION: The incorporation of GA into the evaluation of fetal lung monitoring allows for individualized, GA-specific risk assessment and provides GA-specific cutoffs with increased specificity.

Cohort Studies↗

PubMed2004

Evaluation of two-dimensional cytometric lamellar body counts on the ADVIA 120 hematology system for estimation of fetal lung maturation.

BACKGROUND: We sought to determine if the ADVIA 120 hematology system (Bayer HealthCare LLC, Diagnostics Division, Tarrytown, NY), which employs a unique two-dimensional cytometric analysis approach for platelet (PLT) counting, might also be useful for estimation of LB lamellar body counts in amniotic fluid. METHODS: ADVIA 120 LB counts were performed on 217 amniotic fluid specimens, 88 of which were obtained within 72 h of infant delivery. The ADVIA 120 LB count (ADVIA LB count) results were compared with results from other FLM tests, including the TDx-FLM II (FLM II) test (Abbott Diagnostics, Abbott Park, IL) and the A(650) estimate of lamellar body density using the refractive-index-matched anomalous diffraction (RIMAD) technique. RESULTS: Use of an ADVIA LB count referent value of > or =35,400/microl to indicate maturity, yielded sensitivity, specificity, PV(RDS) and PV(maturity) of 100%, 67.6%, 36.8% and 100%, respectively, in our study population (prevalence of RDS=15.9%). The clinical performance of the ADVIA LB count assay was compared to that of the FLM II and RIMAD assays by predictive value and receiver operating characteristic (ROC) curve analysis. CONCLUSIONS: These data suggest that the ADVIA 120-derived LB counts on amniotic fluid can be useful in predicting fetal lung maturity.

Amniotic Fluid↗

PubMed2002

Prediction of respiratory distress syndrome using the Abbott FLM-II amniotic fluid assay.

BACKGROUND: Most laboratories using the Abbott FLM-II assay for assessing fetal lung maturity follow the manufacturer's recommendations for interpreting the surfactant to albumin ratio (S/A). Thus, values >55 mg/g are considered mature and values <40 mg/g, immature-leaving a wide range of indeterminate values. Little data is available to assist the clinician in interpreting values between 40 and 55 mg/g. The goal of this study was to determine decision levels that would more clearly identify risk for RDS based on S/A results. METHODS: Respiratory distress syndrome was identified based on medical record review in 46 infants (born at six hospitals), who had S/A measurements on amniotic fluid within 72 h of delivery. An additional 257 women, who had had the S/A test requested but had non-RDS infants, were also identified for this study. The probability of RDS was calculated based on S/A values and on gestational age. Odds ratios were computed for different S/A ratios and different gestational ages. RESULTS: Probability of RDS increased with decreasing S/A and decreasing gestational age. At gestational age >36 weeks, the probability of developing RDS ranged from 1% at S/A>44 mg/g to 39% at S/A</=20 mg/g. At gestational age <34, the probability of developing RDS ranged from 14% at S/A>44 mg/g to 92% at S/A</=20 mg/g. CONCLUSIONS: We report a risk-based approach for the clinical interpretation of the results of Abbott FLM-II assays based on a broad range of S/A values and gestational ages.

Albumins↗

PubMed2002

HbA1c as a postmortem tool to identify glycemic control.

Estimates suggest that more than 5A million U.S. citizens unknowingly have diabetes and are at increased risk of morbidity and mortality. We evaluated an immunoturbidimetric measurement of glycated hemoglobin (%HbA1c) as a postmortem tool to identify such individuals. Although postmortem samples undergo some degradation, the effects are not sufficient to invalidate the use of the test or method. Using two study populations whose medical history of diabetes was known, we found the mean %HbA1c of the non-diabetics (5.8+/-0.3) to be statistically different from that of the diabetics (12.4+/-2.8). For the population whose disease status was unknown, the %HbA1c ranged from 4.7 to 16.8. For six unknowns whose values exceeded 7.0%. the mean was 11.7%, which did not differ statistically from the diabetic mean (p = 0.6615). These studies suggest that postmortem blood samples can be used to characterize HbA1c values.

Adolescent↗